Betrixaban, an FDA Fast Track-designated investigational drug, is an oral, once-daily Factor Xa inhibitor anticoagulant. John Curnutte, M.D. Ph.D., executive vice president, research and development at Portola, said:
The I-SPY 2 TRIAL, sponsored by QuantumLeap Healthcare Collaborative (QLHC), is a standing phase 2 randomized, controlled, multicenter study with an innovative adaptive design aimed to rapidly screen
Pablo Lapuerta, M.D., Lexicon’s executive vice president and chief medical officer, said: "The inTandem4 Phase 2 dose-ranging study represents the first of three clinical trials of sotagliflozin that
Debiopharm completed a double-blind randomized phase II study evaluating the efficacy of two different doses of intravenous and oral Debio 1450 compared to intravenous vancomycin and oral linezolid
Oasmia acquires the project and strengthens its oncology project portfolio. Karo Pharma receives 3,080,000 newly issued shares as a down payment corresponding to a value of MSEK 25.
SCD is the most common inherited blood disorder in the United States and is caused by a genetic mutation that results in the production of abnormal hemoglobin, the
Vanda has entered into a License Agreement (the License Agreement) with Taro Pharmaceuticals U.S.A., Inc. and Taro Pharmaceutical Industries Ltd. (collectively, Taro) to resolve Vanda's patent litigation against
The phase 3 Keynote-045 trial demonstrated that Keytruda was superior compared to investigator choice chemotherapy. The drug’s safety profile was consistent with that observed in earlier reported trials
Faron has also recently received the second IDMC (Independent Data Monitoring Committee) recommendation to continue the INTEREST pan-European Phase III trial with Traumakine without any modifications. ARDS is
The first drug candidate within the expanded scope, (CAM2058), is an extended release injectable combination of buprenorphine and granisetron in the FluidCrystal® injection depot technology. CAM2058 has completed
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.